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Fibroblast-secreted hepatocyte growth factor
mediates epidermal growth factor receptor
tyrosine kinase inhibitor resistance in
triple-negative breast cancers through
paracrine activation of Met
Kelly L Mueller1, Julie M Madden1, Gina L Zoratti1,2, Charlotte Kuperwasser3, Karin List1,2 and Julie L Boerner1,2*
Abstract
Introduction: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have shown clinical efficacy
in lung, colon, and pancreatic cancers. In lung cancer, resistance to EGFR TKIs correlates with amplification of the
hepatocyte growth factor (HGF) receptor tyrosine kinase Met. Breast cancers do not respond to EGFR TKIs, even
though EGFR is overexpressed. This intrinsic resistance to EGFR TKIs in breast cancer does not correlate with Met
amplification. In several tissue monoculture models of human breast cancer, Met, although expressed, is not
phosphorylated, suggesting a requirement for a paracrine-produced ligand. In fact, HGF, the ligand for Met, is not
expressed in epithelial cells but is secreted by fibroblasts in the tumor stroma. We have identified a number of
breast cancer cell lines that are sensitive to EGFR TKIs. This sensitivity is in conflict with the observed clinical
resistance to EGFR TKIs in breast cancers. Here we demonstrate that fibroblast secretion of HGF activates Met and
leads to EGFR/Met crosstalk and resistance to EGFR TKIs in triple-negative breast cancer (TNBC).
Methods: The SUM102 and SUM149 TNBC cell lines were used in this study. Recombinant HGF as well as
conditioned media from fibroblasts expressing HGF were used as sources for Met activation. Furthermore, we co-
cultured HGF-secreting fibroblasts with Met-expressing cancer cells to mimic the paracrine HGF/Met pathway,
which is active in the tumor microenvironment. Cell growth, survival, and transformation were measured by cell
counting, clonogenic and MTS assays, and soft agar colony formation, respectively. Student’s t test was used for all
statistical analysis.
Results: Here we demonstrate that treatment of breast cancer cells sensitive to EGFR TKIs with recombinant HGF
confers a resistance to EGFR TKIs. Interestingly, knocking down EGFR abrogated HGF-mediated cell survival,
suggesting a crosstalk between EGFR and Met. HGF is secreted as a single-chain pro-form, which has to be
proteolytically cleaved in order to activate Met. To determine whether the proteases required to activate pro-HGF
were present in the breast cancer cells, we utilized a fibroblast cell line expressing pro-HGF (RMF-HGF). Addition of
pro-HGF-secreting conditioned fibroblast media to TNBC cells as well as co-culturing of TNBC cells with RMF-HGF
fibroblasts resulted in robust phosphorylation of Met and stimulated proliferation in the presence of an EGFR TKI.
Conclusions: Taken together, these data suggest a role for Met in clinical resistance to EGFR TKIs in breast cancer
through EGFR/Met crosstalk mediated by tumor-stromal interactions.
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Introduction
The tyrosine kinase receptor, epidermal growth factor
receptor (EGFR), is a molecule overexpressed in triple-
negative breast cancer (TNBC); that is, estrogen recep-
tor-negative, progesterone receptor-negative, and HER2-
negative. In fact, expression of EGFR is one of the defin-
ing characteristics of TNBC and is a predictor of poor
prognosis [1]. Clinical testing of EGFR tyrosine kinase
inhibitors (TKIs) in breast cancer patients led to the
conclusion that EGFR TKIs are ineffective in treating
this disease [2,3]. However, EGFR TKIs are in clinical
use in lung, colon, and pancreatic cancers [4-6].
As with many targeted therapeutics, acquired resis-
tance to EGFR TKIs is of growing concern in lung can-
cer. One molecule shown to contribute to the acquired
resistance to EGFR TKIs is the tyrosine kinase receptor
Met.
Met is a proto-oncogene that encodes the hepatocyte
growth factor (HGF) receptor. HGF is the only known
ligand of the Met receptor. Met amplification has been
associated with acquired EGFR TKI resistance in lung
cancer cell lines and human lung tumors containing
EGFR tyrosine kinase domain mutations [4,7,8]. Resis-
tance to EGFR TKIs in lung cancers and glioblastomas
was overcome by inhibition of Met activity [9,10]. Met
phosphorylation has also been identified as a contributor
to EGFR TKI resistance in breast cancer [11]. Similar to
the lung cancer models, sensitivity to EGFR TKIs was
increased by co-treating these cells with Met TKIs [11].
However, in contrast to the lung cancer models, breast
cancers are not initially sensitive to EGFR TKIs and
therefore do not develop an acquired resistance in
response to Met upregulation. Breast cancers appear to
be intrinsically resistant to EGFR TKIs and therefore
may regulate Met via a distinct mechanism.
Met has been shown to be phosphorylated promi-
nently in TNBCs. However, Met is not commonly
found to be amplified or mutated in these tumors
[12,13]. Mechanisms of Met activation include both
ligand-dependent and ligand-independent pathways.
Classical activation and subsequent tyrosine phosphor-
ylation of Met involves the processing and activation of
pro-HGF by proteases after binding to the extracellular
domain of Met [14,15]. Christensen and colleagues
summarized a number of ligand-independent methods
of Met phosphorylation in their review, which includes
the following: mutation of Met, constitutive dimeriza-
tion of Met associated with overexpression, pathway
activation via hypoxic conditions, transactivation by
other membrane proteins (including EGFR), and loss of
negative regulators [16]. Many of these mechanisms
are thought to be critical for the contribution of Met
to tumorigenesis.
Here we provide evidence that production of HGF by
neighboring stromal cells is a mechanism for EGFR TKI
resistance in TNBCs. We found that TNBC cell lines
without constitutive activation of Met were sensitive to
EGFR TKIs in culture. Adding exogenous HGF to these
breast cancer cell lines decreased sensitivity to EGFR
TKIs. Knocking down EGFR expression decreased viabi-
lity in TNBC cell lines. In contrast to HGF protecting
cells from loss of cell viability upon inhibition of EGFR
kinase activity, HGF added to cells with knocked down
EGFR expression failed to show a recovery in viability.
This observation suggests that EGFR/Met crosstalk is
critical for mediating EGFR TKI resistance through an
EGFR kinase-independent mechanism. In order to
mimic EGFR/Met crosstalk in the tumor microenviron-
ment we used conditioned media from HGF-producing
fibroblasts as well as co-cultures of TNBCs with these
fibroblasts, and again demonstrated that the activation
of Met mediated EGFR TKI resistance. Taken together,
these data demonstrate that activation of Met in TNBC
cells can stimulate EGFR/Met crosstalk and subsequent
EGFR TKI resistance.
Materials and methods
Cell lines, growth conditions, and reagents
The SUM149 breast cancer cell line was derived from
an invasive ductal mammary carcinoma and the
SUM102 breast cancer cell line was derived from an
intraductal carcinoma with micro-invasion [17]. These
cell lines were obtained from our colleague Dr Stephen
Ethier (Medical University of South Carolina, Charles-
ton, SC, USA). Reduction mammoplasty fibroblasts
expressing human HGF (RMF-HGF) cells were gener-
ated by our co-author Dr Charlotte Kuperwasser (Tufts
University, Boston, MA, USA) [18,19]. SUM149 cells
were grown in 5% IH media (Ham’s F-12 media supple-
mented with 5% fetal bovine serum, 1 μg/ml hydrocorti-
sone, and 5 μg/ml insulin). SUM102 cells were grown in
SFIHE media (Ham’s F-12 media supplemented with 1
μg/ml hydrocortisone, 5 μg/ml insulin, 10 ng/ml epider-
mal growth factor, 5 mM ethanolamine, 10 mM HEPES,
5 μg/ml transferrin, 10 nM triiodo-thyronine, 50 μM
sodium selenite, and 5% BSA). RMF-HGF cells were
grown in DMEM + 10% fetal bovine serum media
(DMEM media supplemented with 10% fetal bovine
serum). All media were supplemented with 2.5 μg/ml
amphotericin B and 25 μg/ml gentamicin sulfate.
The EGFR TKI gefitinib (Iressa) was provided by
AstraZeneca (Wilmington, DE, USA). Erlotinib was pur-
chased from LC Laboratories (Woburn, MA, USA). All
other reagents were purchased from Thermo Fisher
(Waltham, MA, USA) or Sigma (St Louis, MO, USA),
unless indicated.
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Small hairpin RNA knockdown
To downregulate EGFR expression we used small hair-
pin RNA (shRNA) lentiviral particles using commercially
available lentiviral constructs from Open Biosystems
(Huntsville, AL, USA). Twenty-four EGFR shRNA
constructs were screened and validated for EGFR knock-
down. Four constructs targeting different nonoverlap-
ping sequences of the EGFR mRNA were used in the
studies. Specifically, the EGFR sequences targeted by the
shRNAs are as follows: shRNA #1 targets CCAC-
CAAATTAGCCTGGACAA (3,136 base pairs from
ATG), shRNA #2 targets CCGTGGCTTGCATTGATA-
GAA (3,485 base pairs from ATG), shRNA #3 targets
CAGCATGTCAAGATCACAGAT (2,544 base pairs
from ATG), and shRNA #4 targets CCTCCAGAG-
GATGTTCAATAA (149 base pairs from ATG).
The lentiviruses were packaged using a third-genera-
tion lentiviral packaging system developed by Didier
Trono and colleagues (Lausanne, Switzerland) and were
purchased from Addgene (Cambridge, MA, USA) [20].
Specifically, Addgene plasmids pMLDg/pRRE (12251),
pRSV-Rev (12253), and pMD2.G (12259) were trans-
fected into HEK293T cells with the lentiviral vectors
containing the shRNAs using FUGENE6 (Roche, Madi-
son, WI, USA). Cellular supernatant was collected on
days 2 and 3 after transfection, pooled, and filtered. The
lentivirus was titered using HEK293T cells incubated
with increasing concentrations of virus with polybrene
and selected via the puromycin selection on the lenti-
viral vector. Colonies were counted and used to com-
pare viral preps and between viruses for consistent titers
used in experiments. Equal amounts of virus were added
to cells in the presence of polybrene for 4 days prior to
cell lysis or cell viability testing.
Plasmid constructs
Kinase-dead EGFR was cloned into pcDNA3 as pre-
viously described [21]. Mutations were made within the
sequence of EGFR encoded by shRNA #4 to abrogate
shRNA binding to the re-expressed EGFR. Specifically,
shRNA #4 recognizes CCTCCAGAGGATGTTCAA-
TAA. We used site-directed mutagenesis to change the
sequence to TCTCCAAAGGATGTTTAACAA and will
refer to this construct as KD-EGFRmt.
Isolation of conditioned medium
RMF-HGF fibroblasts were cultured to confluence,
switched to serum-free DMEM and cultured for 24 to 48
hours in low-volume conditions (5 ml media/100-mm
dish). Conditioned media were pooled from 24-hour and
48-hour serum-free incubations and HGF was quantified
using a HGF-specific ELISA assay according to the man-
ufacturer’s instructions (R&D Systems, Minneapolis, MN,
USA). Conditioned media were frozen in 1 ml aliquots
and stored at -20°C.
Co-cultures
For the immunoblotting studies, SUM102 or SUM149
cells were plated with RMF-HGF fibroblasts at the indi-
cated cell number ratios for 48 hours in the normal
growth medium of SUM102 or SUM149 cells. Lysates
were prepared and immunoblotted with pMet and b-
actin antibodies. For the BrdU incorporation assays,
SUM102 or SUM149 cells were stained with CellTracker
Green (Life Technologies, Grand Island, NJ, USA) and
RMF-HGF cells were stained with CellTracker Orange.
DNA synthesis was then assessed using BrdU incorpora-
tion for 4 hours after 24 hours of gefitinib treatment.
Cell viability assays
For the MTS assays, cells were plated at 4,000 cells/well
of a 96-well plate in triplicate from parental or EGFR
knockdown cells. For comparison purposes, the parental
cells were treated with 0.5 μM gefitinib with or without
50 ng/ml HGF as indicated. The knockdown cells were
treated with or without 50 ng/ml HGF for 72 hours.
The MTS reagent was added per manufacture directions
(Promega, Madison, WI, USA) and was read using a
Dynex spectrophotometer. The experiment was repeated
three times, with error bars representing the standard
error of the mean.
Cell growth assays
For the proliferation assays the indicated breast cancer
cells were plated in triplicate in six-well plates at 35,000
cells per well (day 0). The next day, and every other day
thereafter for 7 days, the cells were treated with gefitinib
at the indicated dosage. The number of cells was deter-
mined using a Coulter Counter (Beckman Coulter, India-
napolis IN, USA) on days 1, 4, and 8. Each experiment
was repeated at least twice and the graphs represent the
average and standard error of the mean at day 8.
BrdU-incorporation assays
After co-culture with the fibroblasts for 24 hours, 0.5
μM gefitinib was added for an additional 20 hours.
Then 100 μM BrdU was added for 4 hours prior to
fixation of the cells with 4% paraformaldehyde for 20
minutes at room temperature. The cells were then per-
meabilized using 0.01% Triton X-100 for 3 minutes at 4°
C and washed with PBS three times. DNA was then
exposed by incubation of the cells with 2 M HCl for 1
hour at 37°C and neutralized with two borate buffer
washes. The cells were blocked in 20% goat serum for 1
hour at room temperature and incubated with Alexa-
Fluor 594 anti-BrdU conjugated antibody (1:50; Life
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Technologies) for 1 hour at 37°C. Excess antibody was
washed away and the coverslips were mounted, and
BrdU-incorporated nuclei were counted as a ratio of the
total number of cells. One hundred cells were counted
per coverslip, with each experiment performed in
duplicate.
Clonogenic survival assays
Cells were cultured for 7 days with the indicated con-
centration(s) of gefitinib in the presence or absence of
50 ng/ml active HGF or ~110 μM pro-HGF in condi-
tioned media. Cells were trypsinized and plated at 2,000
cells/35-mm dish (without treatment) for 7 days. Colo-
nies were stained with crystal violet and counted.
Soft agar colony formation
Cells were plated in a 0.45% agar noble layer at 250,000
cells/well of a six-well plate. Gefitinib in the presence or
absence of HGF or of HGF-containing conditioned
media was added every other day for 3 weeks. Colonies
were counted using Colony Counter software (Gel
Count, Oxford, United Kingdom) and were averaged.
Immunoblotting
Cells were plated at 1 million cells per 100-mm dish and
cultured for 48 hours. Cells were then lysed in CHAPs
lysis buffer (10 mM CHAPs, 50 mM Tris, pH 8.0, 150
mM NaCl, and 2 mM ethylenediamine tetraacetic acid
with 10 μM NaOVa and 1× protease TKI cocktail; EMD
Biosciences, Billerica, MA, USA). The indicated amount
of protein lysate was separated by SDS-PAGE and trans-
ferred to Immobolin-P. Membranes were blocked in
either 5% nonfat dry milk or 5% BSA for 1 hour at
room temperature. The following primary antibodies
were used in the experiments: anti-EGFR (1:500; Cell
Signaling, Danvers, MA, USA), anti-Met (1:500; Cell Sig-
naling), anti-pMet (1:500; Cell Signaling), and anti-b-
actin (1:10,000; Sigma). The membranes were incubated
with antibodies overnight at 4°C. The membranes were
then washed with Tris-buffered saline + 0.1% Tween-2
three times for 10 minutes each, followed by incubation
with the appropriate secondary antibody, and then with
another series of three washes. Incubation with
enhanced chemiluminescence (GE Biosciences, Piscat-
away, NJ, USA) followed by exposure to film was used
to detect the reactive bands. Each experiment was
repeated at least three times and quantitated using
densitometry.
Results
HGF protects TNBC cells from a gefitinib-induced
decrease in cell growth, survival, and transformation
In the clinic, breast cancers do not respond to EGFR
TKIs; however, a number of EGFR-expressing TNBC
cell lines show sensitivity to EGFR TKIs [3,22] (Figure
1A). Met has been shown to crosstalk with EGFR to
mediate EGFR TKI resistance both in cell culture mod-
els and in patients [7,23-25]. The ligand for Met, HGF
is not expressed in epithelial cells; and Met is not phos-
phorylated in gefitinib-sensitive breast cancer cell lines
[26]. To determine whether activated Met could pro-
mote resistance to EGFR TKIs, two EGFR TKI-sensitive
TNBC cell lines (SUM102 and SUM149) were incubated
with the EGFR TKI gefitinib in the presence or absence
of 50 ng/ml HGF and the cell growth, survival, and
transformation were measured.
SUM102 and SUM149 cells treated with gefitinib
stopped proliferating by day 4 of treatment (Figure 1A,
diamonds). However, when recombinant HGF was pre-
sent (starting at day 1), SUM102 and SUM149 cells con-
tinued to proliferate in the presence of gefitinib (Figure
1A, dotted lines). These data suggest that activation of
Met signaling by HGF is sufficient to stimulate cell
growth when EGFR kinase activity is reduced. Similarly,
HGF increased the clonogenic survival of SUM102 and
SUM149 cells in the presence of gefitinib from 10% to
80% (Figure 1B). Lastly, anchorage-independent growth,
as measured by soft agar colony formation, was
increased four-fold to sixfold over the control after HGF
treatment in the presence of gefitinib (Figure 1C).
Taken together, these data suggest that Met activation
provides an EGFR kinase-independent mechanism of
cell growth, survival, and transformation.
HGF stimulation of cell viability requires EGFR expression
To determine whether HGF was simply signaling
through Met independent of EGFR to increase cell via-
bility, we knocked down EGFR expression and stimu-
lated SUM102 cells with HGF. EGFR was knocked
down using shRNA lentivirus. Four shRNA constructs
targeting different nonoverlapping regions of the EGFR
mRNA were used along with a nonsilencing control.
Two of the shRNA constructs knocked down EGFR
expression more than 90% of the nonsilencing control
(Figure 2A, shRNAs #3 and #4). MTS assays were used
to assess the viability in the presence of the shRNA con-
structs with or without 50 ng/ml HGF. The no-virus
and nonsilencing controls as well as EGFR shRNAs #1
and #2 had no effect on cell viability, correlating with
little to no decrease in EGFR protein expression (Figure
2B, white bars). Interestingly, knocking down EGFR
with EGFR shRNAs #3 and #4 significantly decreased
cell viability (Figure 2B, white bars). These results are
similar to the results we published previously [22].
As shown through the growth, survival, and ancho-
rage-independent growth assays in Figure 1, HGF
increases cell viability in the presence of gefitinib in the
SUM102 cells (Figure 2B, gefitinib). Adding HGF to the
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Figure 1 Hepatocyte growth factor protects triple-negative breast cancer cells from gefitinib treatments. (A) SUM102 and SUM149 cells
were plated at 35,000 cells/well of a six-well plate on day 0. Under normal growth conditions, 50 ng/ml hepatocyte growth factor (HGF) and/or
0.5 μM gefitinib was added to the cells on day 1 and subsequently every other day. Cells were counted on days 1, 4, and 8 using a Coulter
Counter. (B) SUM102 and SUM149 cells under normal growth conditions were treated with increasing concentrations of gefitinib in the presence
or absence of 50 ng/ml HGF for 7 days. Cells were trypsinized and replated at 4,000 cells/35-mm dish and grown under normal growth
conditions for 7 days. Colonies were stained with crystal violet and counted using a cell counter. The percentage of surviving cells was
calculated by dividing the number of colonies on the treated plate by the number of colonies on the untreated plate. (C) Under normal growth
conditions, SUM102 and SUM149 cells were plated in a layer of agar sandwiched between two layers of agar of different percentage. Every
other day for 3 weeks, 50 ng/ml HGF and/or 0.5 μM gefitinib were added to the top layer in a final volume of 300 μl. Colonies were stained
with p-iodonitrol and counted using a cell counter. Each experiment was performed in triplicate at least three times. Student’s t test was used to
determine significance between gefitinib-treated and gefitinib + HGF-treated cells. *P < 0.05. UT, untreated.
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no-virus and nonsilencing controls as well as EGFR
shRNAs #1 and #2 did not significantly change the via-
bility as compared with that of untreated cells (Figure
2B, white vs. black bars). Importantly, when EGFR was
successfully knocked down with EGFR shRNAs #3 and
#4, HGF addition did not significantly increase cell via-
bility (Figure 2B, white vs. black bars). In addition, re-
expression of a kinase-dead EGFR, mutated to be unrec-
ognized by shRNA #4, was able in part to recover the
viability of SUM102 cells treated with HGF (Figure 2A,
B). These data suggest that HGF/Met mediated viability
and that EGFR TKI resistance requires EGFR expression
but not EGFR kinase activity, indicating a critical role
for EGFR/Met crosstalk.
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Figure 2 Hepatocyte growth factor-mediated cell survival requires epidermal growth factor receptor expression. SUM102 cells were
transduced with lentivirus expressing a non-silencing control or four nonoverlapping epidermal growth factor receptor (EGFR) small hairpin RNA
(shRNA) targeting sequences. In addition, SUM102 cells were treated with gefitinib (gef) or hepatocyte growth factor (HGF), or were transfected
with pcDNA3 or KD-EGFRmt as indicated. (A) Four days after transduction and/or transfection, cells were lysed, and lysates were used to
determine expression levels of EGFR via immunoblotting. b-actin was used as a loading control. (B) Duplicate cells were trypsinized and replated
in a 96-well plate. One series of gefitinib-treated cells were used as a control to demonstrate HGF protection from gefitinib treatment (far-left
bar). Remaining cells were treated with or without HGF at 50 ng/ml without gefitinib for 72 hours. In addition, cells were transfected with KD-
EGFRmt at the same time as transduction with shRNA (far-right bar). Cell viability was measured using MTS assays. Numbers under the
immunoblot indicate relative densitometry. Lines indicate comparison samples. Each experiment was performed in triplicate at least three
independent times. *Gef ± HGF, P < 0.001; -HGF ± EGFR knockdown, P = 0.001. N.S., not significant; NV, no virus; NS, nonsilencing. #1, #2, #3,
and #4, arbitrary shRNA clone numbers. KD-EGFR, kinase-dead EGFR; EGFR*, mutated sequence within the shRNA targeting region.
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Conditioned media from HGF-expressing fibroblasts
stimulates clonogenic survival in the presence of gefitinib
HGF is not expressed by epithelial cells and therefore
Met requires HGF to be produced by surrounding stro-
mal cells for ligand-dependent activation [26]. In the
context of breast cancer, fibroblasts are a major compo-
nent of the stroma and have been shown to express
HGF [26]. Single-chain pro-HGF secreted by fibroblasts
binds to Met with high affinity, but it is not signaling
competent unless converted to active two-chain HGF by
endoproteolytic cleavage [15,27]. Therefore, to deter-
mine whether TNBC cells sensitive to EGFR TKIs have
the proper protease(s) to mediate cleavage of pro-HGF,
activation of Met, and subsequent EGFR/Met crosstalk,
we utilized conditioned media from a human fibroblast
cell line engineered to express human HGF (RMF-HGF)
[18,19]. We confirmed that HGF was present in its inac-
tive single-chain form by western blotting in agreement
with previous published reports (data not shown and
[28]).
The amount of pro-HGF in the conditioned media
from the RMF-HGF was quantitated using an ELISA
assay and ~100 nM pro-HGF was used for the experi-
ment. Pro-HGF-conditioned media stimulated phos-
phorylation of Met in both the SUM102 and SUM149
cell lines (Figure 3A, CM). This phosphorylation of Met
was not changed by co-treatment with the EGFR TKI
gefitinib (Figure 3A, gef + CM). Clonogenic cell survival
assays were performed with co-treatment of SUM102
and SUM149 with 0.5 μM gefitinib and/or 100 nM HGF
conditioned media. Similar to treating the cells with
recombinant HGF, pro-HGF stimulated clonogenic sur-
vival in the presence of gefitinib in both SUM102 and
SUM149 cells (Figure 3B). To verify the significance of
these findings, SUM102 cells were treated with another
EGFR TKI, erlotinib, at 0.5 μM with 100 nM HGF-con-
ditioned media and analyzed in a similar clonogenic
assay. As seen with gefitinib, HGF-conditioned media
protect SUM102 cells from erlotinib. These data suggest
that SUM102 and SUM149 cells contain the one or
more proteases capable of activating pro-HGF to active
HGF, which induces Met phosphorylation and mediates
subsequent EGFR/Met crosstalk.
Co-cultures of HGF-expressing fibroblasts and TNBCs
stimulate Met phosphorylation and DNA synthesis in the
presence of gefitinib
To mimic the tumor microenvironment we performed
co-culture experiments with RMF-HGF fibroblasts and
SUM102 or SUM149 cells. SUM102 cells were co-cul-
tured with RMF-HGF fibroblasts at various ratios and
the phosphorylation of Met was determined. Using
semi-quantitative densitometry to compare phosphory-
lated Met with total Met, co-culturing SUM102 cells
with RMF-HGF fibroblasts increased Met phosphoryla-
tion with an increasing number of fibroblasts plated
(Figure 4A, numbers below the immunoblot). RMF-
HGF fibroblasts do not express Met and therefore are
unable to stimulate Met phosphorylation in an autocrine
fashion (Figure 4A, last lane). To determine whether the
co-culture of RMF-HGF fibroblasts with SUM102 or
SUM149 cells would rescue gefitinib-induced cell
growth inhibition, BrdU incorporation after gefitinib
treatment was quantitated (Figure 4B). BrdU incorpora-
tion was counted only in the SUM102 or SUM149 cells
as identified by CellTracker green staining. As expected,
BrdU incorporation was significantly reduced with gefiti-
nib treatment (Figure 4B, gef). When the breast cancer
cells were co-cultured with RMF-HGF fibroblasts, how-
ever, they were significantly less sensitive to gefitinib
(Figure 4B, gef, white vs. black bars). These data pro-
vide, for the first time, evidence of a mechanism for
EGFR TKI resistance in breast cancer: EGFR/Met cross-
talk through interaction between stromal fibroblasts and
cancer cells.
Discussion
We have herein described a mechanism for EGFR TKI
resistance in TNBC cells through activation of Met by
its ligand HGF. Specifically, we found that HGF
increased growth, clonogenic survival, and anchorage-
independent growth in the presence of the EGFR TKI
gefitinib. This enhanced growth in the presence of HGF
and gefitinib was dependent on EGFR expression
because knocking down EGFR expression decreased sur-
vival in the presence of gefitinib independent of HGF
treatment. In addition, conditioned media from fibro-
blasts producing HGF as well as co-cultures with these
fibroblasts stimulated Met phosphorylation and survival
in the presence of gefitinib. Taken together, these results
describe a role for stromal-produced HGF in intrinsic
resistance to EGFR TKIs in TNBCs.
Crosstalk between EGFR and Met has been reported
in breast, lung, and brain cancers [29]. This crosstalk
has been suggested to occur via EGFR phosphorylation
of Met as well as Met phosphorylation of EGFR. Phos-
phorylation of EGFR by Met has been shown to occur
via direct as well as indirect mechanisms. With respect
to direct phosphorylation, several groups, including our
own, have demonstrated that Met associates with EGFR
and that this association mediates transphosphorylation
of EGFR [23,30]. Indirect methods of Met phosphoryla-
tion of EGFR include Met-dependent upregulation of
EGFR ligands [31-33] and Met-dependent activation of
other tyrosine kinases (for example, c-Src) [11]. The
functional significance of this crosstalk has been
reported by several groups. Engelman and colleagues
demonstrated that crosstalk between EGFR and Met
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was mediated by phosphorylation and signaling from
HER3 to Akt in lung cancer cell lines and that this
crosstalk mediated resistance to EGFR TKIs [7]. We
have previously shown that inhibiting Met kinase activ-
ity in breast cancer cell lines with constitutive Met
activation sensitizes these cells to EGFR TKIs [11]. Here
we expand our knowledge about Met/EGFR crosstalk by
demonstrating not only that inhibition of Met increases
sensitivity to EGFR TKIs, but also that activation of Met
by HGF indeed promotes resistance to EGFR TKIs in
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Figure 3 Hepatocyte growth factor stimulates Met phosphorylation and enhances clonogenic survival in the presence of gefitinib.
(A) SUM102 and SUM149 cells were cultured with condition media from RMF-HGF fibroblasts for 1 hour in the presence or absence of 0.5 μM
gefitinib (gef). Lysates were prepared and analyzed for Met phosphorylation using immunoblotting. Met and b-actin expression levels were used
as controls. CM, pro-hepatocyte growth factor (pro-HGF) conditioned media; UT, untreated. (B) SUM102 and SUM149 cells were treated with
conditioned media from RMF-HGF fibroblasts in the presence or absence of the indicated concentration of gefitinib or erlotinib for 7 days,
adding fresh drug and conditioned media (CM) every other day. Cells were trypsinized, replated, and grown under normal growth conditions for
7 days. Colonies were stained using crystal violet and counted using a cell counter. Each experiment was performed in triplicate at least three
times. Student’s t test was used to determine survival differences between gefitinib-treated cells in the presence or absence of conditioned
media.
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TNBC cell lines. These data are supported by the work
of others in which lung cancer cell lines containing
activating mutations of EGFR that mediate sensitivity
to EGFR TKIs can be made resistant in the presence of
HGF [24]. In addition, Zhang and colleagues used a
novel mouse model to demonstrate that HGF expres-
sion can promote tumor growth of EGFR-expressing
breast cancers [25,34]. We have now demonstrated a
role for HGF in conferring EGFR TKI resistance to
TNBC cells.
In breast cancer, Met is thought to be activated
through association with co-receptors or by binding to
its ligand HGF produced by the tumor-associated
stromal cells. Hochgrafe and colleagues found that Met
is phosphorylated in breast tumors and that the phos-
phorylation of EGFR and Met is enriched in TNBC
tumors [35]. EGFR and Met are expressed at high levels
in these tumors and are both independent characteristic
markers for TNBCs [36,37]. Expression of HGF, the
ligand for Met, is limited to cells of mesenchymal origin,
suggesting that communication between the tumor and
the stroma is required for Met activation [26]. Here we
have shown that HGF produced by human fibroblasts
mediates Met phosphorylation and subsequent resis-
tance to EGFR TKIs in TNBC cell lines. In addition, we
have demonstrated in a co-culture system that HGF
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Figure 4 Met phosphorylation and DNA synthesis in triple-negative breast cancer cells in the presence of gefitinib. Co-culture with
hepatocyte growth factor (HGF)-expressing fibroblasts increases Met phosphorylation and DNA synthesis in triple-negative breast cancer cells in
the presence of gefitinib. (A) SUM102 cells were labeled with CytoTracker green and were co-cultured with RMF-HGF cells at different ratios.
Lysates were analyzed for phosphorylation of Met by immunoblotting. b-actin and total Met protein expression were used as controls. Numbers
below the immunoblots represent relative densitometry measurements of the ratio of pMet to total Met. (B) RMF-HGF fibroblasts were plated on
coverslips. SUM102 and SUM149 cells were labeled with CytoTracker green and plated on top of the RMF-HGF fibroblasts at the indicated ratios.
Then 1.0 μM gefitinib (gef) was added to the cells for 24 hours. SUM102 cells were incubated with BrdU for 18 hours and SUM149 cells were
incubated with BrdU for 4 hours. Cells were fixed and stained using anti-BrdU-Alexa-Fluor-595. SUM102 and SUM149 cells labeled green were
counted as BrdU-positive or BrdU-negative. Student’s t test was used to determine statistical significance between gefitinib-treated cells with or
without co-cultures. *SUM102, P = 0.0471; SUM149, P = 0.0028. UT, untreated; 0/10, fibroblast to tumor cell ratio; 10/10, fibroblast to tumor cell ratio.
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produced by neighboring fibroblasts promotes resistance
to EGFR TKIs in SUM102 and SUM149 cells. We have
thus provided evidence for the crosstalk between EGFR
and Met to be mediated through interactions between
the tumor cell and the microenvironment in TNBCs.
Conclusions
TNBC is a subtype of breast cancer that overlaps with
the basal-like breast cancers lacking estrogen receptor/
progesterone receptor and HER2 expression. While the
survival rates of women with estrogen receptor-positive
and HER2-positive breast cancers have increased with
the development of tamoxifen and herceptin, respec-
tively [38,39], TNBCs retain the lowest 5-year survival
rates [1]. The EGFR is overexpressed in 54% of TNBCs,
yet EGFR TKIs remain ineffective for their treatment
[2,3]. Our data here support the hypothesis that this
lack of efficacy in clinical treatment of breast cancers
with EGFR TKIs is due to crosstalk between EGFR and
Met. In combination with our previous data and those
of others, these results suggest that targeting EGFR and
Met in combination in TNBC may be an effective thera-
peutic strategy.
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